Prolyl endopeptidase (PE), a protease that cleaves after proline residues in oligopeptides, is highly active in brain and degrades neuropeptides in vitro. We have recently demonstrated that PE, in concert with MMP's, can generate PGP (proline-glycine-proline), a novel, neutrophil chemoattractant, from collagen. In this study, we demonstrate that human peripheral blood neutrophils contain PE, which is constitutively active, and can generate PGP de novo from collagen after activation with LPS. This novel, pro-inflammatory role for PE raises the possibility of a self-sustaining pathway of neutrophilic inflammation and may provide biomarkers and therapeutic targets for diseases caused by chronic, neutrophilic inflammation.
Introduction
Prolyl endopeptidase (PE) is an endopeptidase, which cleaves at the carboxyl side of proline residues in oligopeptides. PE is the only prolinespecific endopeptidase currently known in mammals and belongs to a group of serine proteases, which also includes dipeptidyl peptidase IV, oligopeptidase B and acylaminoacyl peptidase (Polgar, 2002) . These peptidases differ significantly from classical serine proteases, such as trypsin or subtilisin, in their structure and selectivity for small peptide substrates. In PE, the catalytic triad is covered by the central tunnel of a β propeller domain, which excludes peptides larger than 30-100 amino acids from the active site (Fulop et al., 1998) .
Peptide bonds involving proline residues are seldom cleaved by classical serine proteases since they do not fit into the catalytic site. Many biologically active peptides contain prolines within their amino acid sequence and enzymes that cleave peptides at a proline may consequently have important biological effects (Cunningham and O'Connor, 1997; Mentlein, 1988) . PE is highly active in brain tissue (Kalwant and Porter, 1991) , degrades neuropeptides in vitro (Knisatschek and Bauer, 1979; Taylor and Dixon, 1980; Wilk et al., 1979) and may play a role in the pathogenesis of depression and Alzeheimer's disease (Maes et al., 1994; Rossner et al., 2005) . PE inactivates bradykinin, a vasodilator, and converts angiotensin I and II to angiotensin (residues 1-7), which liberates vasopressin from the hypothalamus, and may play a role in hypertension (Welches et al., 1993) . However, the physiologic function of PE remains obscure despite its ubiquitous presence in human tissues as well as serum (Goossens et al., 1996) .
We have recently identified a novel pathway signaling neutrophil influx to the lung in which PE plays a major role. Chemical or enzymatic breakdown of collagen releases a tripeptide, proline-glycine-proline (PGP) that is chemotactic for neutrophils in vitro and in vivo (Weathington et al., 2006) . The neutrophil chemotactic activity of PGP may be due to a marked structural relatedness to a receptor-binding domain of CXC chemokines, such as interleukin-8, which contain this collagen sequence or a close analog. PGP production from collagen is dependent on initial digestion of collagen by MMP-8 and MMP-9 with PE catalyzing the final reaction (Gaggar et al., 2008) . PGP and PE are elevated in lung diseases characterized by chronic, neutrophilic, airway inflammation. Sputum from patients with chronic obstructive pulmonary disease (COPD) or cystic fibrosis (CF) contains increased amounts of PGP and generates PGP from collagen in a PE-dependent fashion (Gaggar et al., 2008; O'Reilly et al., 2009 ). PE activity is elevated in sputum from CF patients and bronchoalveolar lavage fluid from lung transplant patients with chronic allograft rejection (Gaggar et al., 2008; Hardison et al., 2009 ). To our knowledge, this is the first time PE has been implicated in inflammation or in disorders of the respiratory system.
Given the detection of PE in neutrophilic lung diseases, we hypothesized that neutrophils might be a source of PE. We demonstrate herein, using a variety of molecular and biochemical techniques, that human peripheral blood neutrophils contain constitutively active PE 
